Carbon-13 and carbon-14 labeled dabigatran etexilate and tritium labeled dabigatran

Autor: Bachir, Latli, Ralf, Kiesling, Stefan, Aßfalg, Max, Chevliakov, Matt, Hrapchak, Scot, Campbell, Nina, Gonnella, Carl A, Busacca, Chris H, Senanayake
Rok vydání: 2016
Předmět:
Zdroj: Journal of labelled compoundsradiopharmaceuticals. 59(14)
ISSN: 1099-1344
Popis: Dabigatran etexilate or pradaxa, a novel oral anticoagulant, is a reversible, competitive, direct thrombin inhibitor. It is used to prevent strokes in patients with atrial fibrillation and the formation of blood clots in the veins (deep venous thrombosis) in adults who have had an operation to replace a hip or a knee. Pradaxa is the only novel oral anticoagulant available with both proven superiority to warfarin and a specific reversal agent for use in rare emergency situations. The detailed description of the synthesis of carbon-13 and carbon-14 labeled dabigatran etexilate, and tritium labeled dabigatran is described. The synthesis of carbon-13 dabigatran etexilate was accomplished in eight steps and in 6% overall yield starting from aniline
Databáze: OpenAIRE